Login to Your Account



in the clinic NEWS

Shares in Innate Pharma SA fell 14 percent Thursday on news that a DSMB called a halt to one treatment arm of a phase II trial in AML testing lirilumab (IPH2102, BMS-986015), an immunotherapeutic antibody that targets inhibitory KIRs expressed by NK cells.

For VBL Therapeutics Inc., positive interim top-line phase II data with its gene therapy for recurrent glioblastoma took the sting out of February's news with a separate compound targeting psoriasis and ulcerative colitis, also each in a phase II trial.

Lpath Inc. saw its shares tumble in heavy trading following the release of news that its phase IIa single-agent, open-label study of Asonep did not meet the primary endpoint of statistically significant PFS in patients with advanced RCC.
More in the clinic Headlines

Cast Your Vote

Has biotech’s bubble burst?: